Conference Reports for NATAP
EASL 2024
June 5-8, Milan, Italy
Back
Efficacy and Safety of 144 Weeks of Bulevirtide 2 mg or
10 mg Monotherapy From the Ongoing Phase 3 Study MYR301
Pietro Lampertico
